The promise of bispecific antibodies: Clinical applications and challenges

Sun Min Lim, Kyoung Ho Pyo, Ross A. Soo, Byoung Chul Cho

Research output: Contribution to journalReview articlepeer-review

12 Citations (Scopus)

Abstract

The development of cancer therapies using monoclonal antibodies has been successful during the last 30 years. Recently much progress was achieved with technologies involving bispecific and multi-specific antibodies. Bispecific antibodies (BsAbs) are antibodies that bind two distinct epitopes, and a large number of potential clinical applications of BsAbs have been described. Here we review mechanism of action, clinical development and future challenges of BsAbs which could be a serve as a valuable arsenal in cancer patients.

Original languageEnglish
Article number102240
JournalCancer Treatment Reviews
Volume99
DOIs
Publication statusPublished - 2021 Sep

Bibliographical note

Funding Information:
RAS- Advisory Board: Amgen, Astra-Zeneca, Bayer, BMS, Boehringer Ingelheim, Lilly, Merck, Novartis, Puma Biotechnology, Pfizer, Roche, Taiho, Takeda, Yuhan and research grants from Astra-Zeneca, Boehringer Ingelheim.

Publisher Copyright:
© 2021 Elsevier Ltd

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint

Dive into the research topics of 'The promise of bispecific antibodies: Clinical applications and challenges'. Together they form a unique fingerprint.

Cite this